SynthesisBMC gastroenterology2026
The role of machine perfusion in preventing recurrence after liver transplant for hepatocellular carcinoma: a systematic review and meta-analysis.
Synthesis in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatocellular carcinoma (HCC) is a leading indication for liver transplantation (LT), but post-transplant recurrence remains a major cause of treatment failure. Ischemia-reperfusion injury (IRI) has been implicated in tumor recurrence through modulation of the hepatic microenvironment. Machine perfusion (MP) techniques reduce IRI and may improve oncologic outcomes. This systematic review and meta-analysis evaluated the impact of MP versus static cold storage (SCS) on HCC recurrence following LT.
methodsA systematic search of PubMed, CENTRAL, Scopus, Google Scholar and ClinicalTrials.gov was conducted from database inception to January 31, 2026. Studies comparing HCC recurrence after LT using MP or SCS graft preservation were included. The primary outcome was post-transplant HCC recurrence. Secondary outcomes included microvascular invasion (MVI), pre-transplant alpha-fetoprotein (AFP), Milan criteria status, and neoadjuvant therapies. Pooled odds ratios (ORs) and standardized mean differences (SMDs) with 95% confidence intervals (CIs) were calculated using RevMan 5.4.1.
resultsTen studies involving 6,652 patients (4,944 SCS and 1,708 MP) were included. Nine studies evaluated hypothermic oxygenated perfusion and one assessed ischemia-free liver transplantation. Meta-analysis demonstrated a significantly higher risk of HCC recurrence in the SCS group compared with the MP group (OR 2.34, 95% CI 1.40-3.91; p = 0.001; I²=53%). Sensitivity analysis confirmed the robustness of the finding (OR 2.26, 95% CI 1.48-3.45; p = 0.0002; I²=22%). Subgroup analysis restricted to hypothermic oxygenated perfusion also favored MP (OR 1.97, 95% CI 1.25-3.10; p = 0.003). No significant differences were observed between groups regarding pre-transplant AFP levels (SMD 0.02, 95% CI - 0.09 to 0.13; p = 0.68), Milan criteria status (OR 0.83, 95% CI 0.59-1.19; p = 0.32), use of neoadjuvant therapies, or MVI.
conclusionsMachine perfusion for liver graft preservation is associated with a lower risk of HCC recurrence after liver transplantation compared with static cold storage. This benefit appears independent of baseline tumor characteristics and pre-transplant treatments. Given the predominance of retrospective studies, further prospective multicenter studies and randomized controlled trials are needed to confirm these findings and define the oncologic role of machine perfusion in liver transplantation for HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.